<!DOCTYPE html>
        
<html lang="zh-Hant-TW">
		<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<meta name="generator" content="Hugo 0.65.3" />
	
	<link rel="icon" href="http://www.4stack.pro/img/logo.png">
	
	<title>暫停在中國進行的 remdesivir 治療 COVID-19 試驗！ Gilead 的下一步？ | Rumor Theory</title>
	
	

	<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="暫停在中國進行的 remdesivir 治療 COVID-19 試驗！ Gilead 的下一步？"/>
<meta name="twitter:description" content="Remdesivir 是一種通用型 RNA 聚合酶抑制劑，對 Ebola virus、SARS-Co"/>

	<meta property="og:title" content="暫停在中國進行的 remdesivir 治療 COVID-19 試驗！ Gilead 的下一步？" />
<meta property="og:description" content="Remdesivir 是一種通用型 RNA 聚合酶抑制劑，對 Ebola virus、SARS-Co" />
<meta property="og:type" content="article" />
<meta property="og:url" content="http://www.4stack.pro/news/pause-remdesivir-conducted-in-chinese-treatment-covid-19-test-gilead-s-next-/" />
<meta property="article:published_time" content="2020-04-17T08:58:44+08:00" />
<meta property="article:modified_time" content="2020-04-17T08:58:44+08:00" />




    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/latest/css/font-awesome.min.css" />
    
    
    <link href="http://www.4stack.pro/css/bootstrap.min.css" rel="stylesheet" />
    <link href="http://www.4stack.pro/css/demo.css" rel="stylesheet" />
    <link href="http://www.4stack.pro/css/navbar-top-fixed.css" rel="stylesheet" />



 





  
  <meta property="og:image" content="http://www.4stack.pro/news/pause-remdesivir-conducted-in-chinese-treatment-covid-19-test-gilead-s-next-/cover.jpg" />





 



	<meta name="keywords" content=""/>
	<meta name="description" content=""/>


	<link href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous">
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.0.13/css/all.css" integrity="sha384-DNOHZ68U8hZfKXOrtjWvjxusGo9WQnrNx2sqG0tfsghAvtVlRW3tvkXWZh58N9jp"
	 crossorigin="anonymous">
	<link href="https://fonts.googleapis.com/css?family=Righteous%7CMerriweather:300,300i,400,400i,700,700i" rel="stylesheet">
	<link href="http://www.4stack.pro/css/medium.css" rel="stylesheet">
	<link href="http://www.4stack.pro/css/additional.css" rel="stylesheet">
	<script async src="//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>

<script data-ad-client="ca-pub-2730293094729387" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="application/ld+json">


{
  "@context": "https://schema.org",
  "@type": "Organization",
  "name": "Rumor Theory",
  "url": "http://www.4stack.pro/",
  "sameAs": [
    "https://www.facebook.com/m.media168"
  ]
}

</script>
</head>
<body>


 <nav class="navbar navbar-expand-md navbar-dark fixed-top bg-dark">
      <a class="navbar-brand" href="http://www.4stack.pro/">M media</a>
	  &nbsp; <div id="navbar_top" name="navbar_top"></div>
      <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
        <span class="navbar-toggler-icon"></span>
      </button>

      <div class="collapse navbar-collapse" id="navbarCollapse">
        <ul class="navbar-nav mr-auto" id="mymenu">
        </ul>
      </div>
    </nav>






        <div class="site-content">   
            <div class="container">
<div class="main-content">
        
        <div class="container">
            <div class="row">
                
                <div class="col-md-2 pl-0"><div class="share sticky-top sticky-top-offset">
    <p>Share</p>
    <ul>
        <li class="ml-1 mr-1">
        <a target="_blank" href="https://twitter.com/intent/tweet?text=%e6%9a%ab%e5%81%9c%e5%9c%a8%e4%b8%ad%e5%9c%8b%e9%80%b2%e8%a1%8c%e7%9a%84%20remdesivir%20%e6%b2%bb%e7%99%82%20COVID-19%20%e8%a9%a6%e9%a9%97%ef%bc%81%20Gilead%20%e7%9a%84%e4%b8%8b%e4%b8%80%e6%ad%a5%ef%bc%9f&url=http%3a%2f%2fwww.4stack.pro%2fnews%2fpause-remdesivir-conducted-in-chinese-treatment-covid-19-test-gilead-s-next-%2f" onclick="window.open(this.href, 'twitter-share', 'width=550,height=435');return false;">
        <i class="fab fa-twitter"></i>
        </a>
        </li>
        
        <li class="ml-1 mr-1">
        <a target="_blank" href="https://facebook.com/sharer.php?u=http%3a%2f%2fwww.4stack.pro%2fnews%2fpause-remdesivir-conducted-in-chinese-treatment-covid-19-test-gilead-s-next-%2f" onclick="window.open(this.href, 'facebook-share', 'width=550,height=435');return false;">
        <i class="fab fa-facebook-f"></i>
        </a>
        </li>

        <li class="ml-1 mr-1">
        <a target="_blank" href="https://www.xing.com/spi/shares/new?url=http%3a%2f%2fwww.4stack.pro%2fnews%2fpause-remdesivir-conducted-in-chinese-treatment-covid-19-test-gilead-s-next-%2f" onclick="window.open(this.href, 'xing-share', 'width=550,height=435');return false;">
        <i class="fab fa-xing"></i>
        </a>
        </li>        
    </ul>

    
</div>
</div>
                                
                <div class="col-md-9 flex-first flex-md-unordered">
                    <div class="mainheading">
                        	
                                                
                        
                        <h3 class="posttitle">暫停在中國進行的 remdesivir 治療 COVID-19 試驗！ Gilead 的下一步？</h3> 
                    </div>

                    
                    
                    
                    

                    
                    <div class="article-post">

						 <p><img src="https://geneonline.news/wp-content/uploads/2020/04/COVID-1.jpg" alt="img">
Remdesivir 是一種通用型 RNA 聚合酶抑制劑，對 Ebola virus、SARS-CoV、 MERS-CoV、Nipah virus 等多種 RNA 病毒都有不錯的抑制效果。它在細胞與動物試驗顯示能抑制 SARS-CoV-2 複製的效果。美國有幾例成功治癒的病例，中國隨後開啟該藥的臨床試驗。Gilead 已經免費生產 150 萬瓶該藥，正在用這種藥物治療患者。</p>
<p>由於缺乏合格的 COVID-19 輕症和中症患者，Gilead 於 4 月 15 日中止了 remdesivir 在中國的第三期試驗。許多投資者都對此表示震驚。另外，該公司進行至少 5 項 remdesivir 治療 COVID-19 臨床試驗。</p>
<p>根據 RBC 分析師 Brian Abrahams 的報告指出，該公司正在繼續對重症患者進行研究，並從暫停的試驗中提取數據。Gilead 資助的重症患者試驗結果預計 4 月下旬發佈，儘管缺乏控制組可能會限制解釋性，以及預計 5 月公布中度患者試驗結果，這些都是關鍵數據。另外，由美國國家過敏和傳染病研究所（NIAID）進行的 remdesivir 臨床試驗結果也可望最早在 5 月發佈。</p>
<p>隨後，Abrahams 解釋所有這一切均暗示該藥的療效有限，他寫道：“我們仍然相信，儘管雷姆昔韋在最近的公開標籤富有同情心的使用公開發表的數據中顯示出有希望的活性信號，但事實並未顯示截短的嚴重性儘管目前的更新也表明，該研究在中國是迄今為止唯一的隨機研究，但仍表明該研究招募了相當多的患者（n = 237），表明觀察到的任何益處均未得出結論，並維持了我們的觀點，即瑞地昔韋顯示出大量活動的可能性仍保持最佳50/50。”</p>
<p>到目前為止，已有 1800 多名患者同意接受 remdesivir 治療。該研究團隊也於近日在《The New England Journal of Medicine》上發表了 53 例患者的臨床數據，顯示不錯的治療結果。所有患者接受該藥治療長達 10 天。在 18 天後，有 68％ 的患者表現出改善，其中在 30名使用呼吸器的患者中，有 17 名患者可以摘下設備。幾乎一半的病人出院，而 13％ 的病人死亡。接受通氣治療的患者死亡率最高，有 18％ 死亡。</p>
<p>本實驗沒有對照組，因此很難得出任何明確的結論。對此，倫敦衛生與熱帶醫學學院藥物流行病學 Stephen Evans 教授表示，本文的數據幾乎無法解釋，有一些證據表明有療效，他們如果不給患者藥物治療，這些患者會發生什麼事。</p>
<p>然而，另一位 Oppenheimer 的 Hartaj Singh 分析師較樂觀地表示，雖然他也擔憂研究沒有任何對照組，但這些結果完全是有方向性的。另外，在美國、歐盟、加拿大和日本進行該藥的臨床試驗可能有不同的臨床規劃，具體取決於患者所在的醫療系統。在不同的試驗中，甚至用該藥物治療的療程似乎也有所不同，這將使得很難準確地確定 remdesivir 的正確使用劑量。</p>
<p>Needham 分析師 Alan Carr 表示，如果發現該藥物對 COVID-19 有幫助，Gilead 則在評估後續批次的定價策略選擇。即使該藥物對疫情僅有一些幫助，也可能會有巨大的需求。但是在全球大流行中，它不太可能成為 Gilead 的任何利潤中心。</p>
<p>延伸閱讀：Remdesivir 還是 Lopinavir？COVID-19 新型冠狀病毒藥物治療現況</p>
<p>參考資料：</p>
<ol>
<li>
<p><a href="https://www.biospace.com/article/gilead-shutters-covid-19-trial-in-china-stocks-drop-3-percent-/">https://www.biospace.com/article/gilead-shutters-covid-19-trial-in-china-stocks-drop-3-percent-/</a></p>
</li>
<li>
<p><a href="https://finance.yahoo.com/news/gilead-sciences-remdesivir-could-silver-145309358.html">https://finance.yahoo.com/news/gilead-sciences-remdesivir-could-silver-145309358.html</a></p>
</li>
</ol>
<p>©www.geneonline.news. All rights reserved. 基因線上版權所有 未經授權不得轉載。合作請聯繫：[email protected]


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>


<h3 id="生醫股remdesivir仍屬原廠臨床階段-中化生暫不規畫上市時程">《生醫股》Remdesivir仍屬原廠臨床階段 中化生：暫不規畫上市時程</h3>
<p><img src="https://s.yimg.com/os/mit/media/p/common/images/favicon_new-7483e38.svg" alt="img">
政治</p>
<p>中央社</p>
<p>（中央社記者戴雅真倫敦2020年4月16日專電）「經濟學人」（The Economist）報導，中國正在發動大外宣，向各國贈送醫療設備的同時，要確保這些畫面全被攝影機記錄下來，要全世界都記得要「感謝老大哥」。報導指出，中國聲稱這是中共掌權以來最大的援助行動，媒體版面幾乎沒有一天未出現中國提供口罩、呼吸器等醫療設備以及中國醫療團隊到國外協助防疫的新聞。才不過幾週前，中國自己是這場疫情的最大受害者，北京政府廣受指責掩蓋疫情。現在中國試圖改變形象，扮演控制疫情的模範生、全世界的救贖者。中國官媒鉅細彌遺報導每一筆對外援助，不論金額多小。3月21日，一列火車從中國浙江的義烏市駛向西班牙馬德里，載運11萬個口罩與近800套防護服，要捐給西班牙的國有機構。這筆捐助價值不到5萬美元（約新台幣150萬元），卻被中國國營媒體稱為打造「健康絲綢之路」的「新轉折點」。報導指出，中國這種轉移視線的作法一點也不令人驚訝。中國的疫情數據真實性雖令人質疑，但此作法卻成效顯著，幾乎所有新增病例都來自境外。中國身為絕大多數醫療用品的最大生產國，隨著國內需求下降，中國準備好要伸出援手，中國發言人聲稱是「助人助己」。不過，中國也想從中獲得潛在的政治回報，其中最大回報是推廣在海外勢力。即使在疫情之前，中國就已經在與美國競爭全球最具影響力的地位。現在美國深陷疫情，美國總統川普還在摸索如何應對，這是中國的機會。中共想要的另一項政治收穫是藉由幫助他國，以及宣傳這些國家渴望學習中國的成功防疫經驗，轉移在疫情初期掩蓋事實而遭受的批評。中國官媒宣傳，中國防疫展現中國特色社會主義的優勢，並把中國國家主席習近平的招牌擦亮，協助宣傳。習近平和每一名世界領導人通電話討論疫情，都會登上國家電視台晚間新聞的頭條。報導指出，中共這次大外宣使用習近平過去的招牌用詞。以運送物資到馬德里的新聞為例，「健康絲綢之路」這個詞彙習近平在2017年使用過。他當年到日內瓦訪問世界衛生組織（WHO），提出中國歡迎世衛參與一帶一路，共建「健康絲綢之路」。中國國內部分評論員表示，中國援外物資是擴展「軟實力」的機會。軟實力是共產黨在2007年黨代表大會中提出的論點，從此成為中國重大戰略之一。習近平尤其重視軟實力，包括設立孔子學院，以及對西方觀眾宣傳美化過的中國新聞。在這次疫情中，中國官媒與中國駐外使館的推特與臉書帳號（中國本土禁用）都不斷推廣中國善舉。專家指出，推特有上萬假帳號在宣傳不實訊息。然而，中國想要贏得各國的心不容易。畢竟，正當中國一方面宣傳善舉的同時，捐贈價值卻遠不及中國企業賣出的醫療設施（買家稱劣質品時有所聞）。從3月1日至4月4日，中國向全國出口價值14.5億美元（約新台幣435億元）醫療設備。在歐洲某些地方，中國的援助確實得到仰慕。塞爾維亞首都貝爾格勒（Belgrade）的街頭就豎立了巨大的看板，上頭有習近平頭像，還用中文寫著「感謝您，習大哥」。智庫學者波傑提（Lucrezia Poggetti）表示，那些不滿歐盟，又對川普不信任的民眾，就會買中國的賬。義大利電視台這個月進行民調，詢問民眾在歐洲國家之外選擇一個盟國，800名受訪者有36%傾向中國，30%選擇美國。不過對於大多數西方國家，中國的宣傳手法令人白眼，也對西方給予的援助太過健忘。美國與歐洲在2月初捐贈中國30噸醫療物資。法國總統馬克宏（EmmanuelMacron）抱怨民眾只稱讚中國與俄國給予歐洲援助，「沒有人提到法國和德國給了義大利200萬個口罩和上萬套防護衣」。（編輯：周永捷）1090417


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>


<h3 id="gileads-remdesivir-looks-promising-in-leaked-early-results-but-dont-jump-to-conclusions-analyst">Gilead&rsquo;s remdesivir looks promising in leaked early results, but don&rsquo;t jump to conclusions: analyst</h3>
<p><img src="https://qtxasset.com/fiercebiotech/1587077961/Screen%20Shot%202020-04-06%20at%2011.50.06%20AM.png/Screen%20Shot%202020-04-06%20at%2011.50.06%20AM.png?sKXF1i9bYCSNohAczm.0pMGcH.Zv68dJ" alt="img">
The world is watching and waiting for data to see whether Gilead&rsquo;s investigational antiviral remdesivir can help fight COVID-19. And while some leaked early results suggest that it can, industry watchers will need to wait for data from Gilead&rsquo;s own controlled phase 3 study to know for sure.</p>
<p>Researchers at the University of Chicago Medical Center, which is treating patients with severe COVID-19, have seen remdesivir swiftly tamp down both fever and respiratory symptoms, according to a report from Stat. Gilead’s shares leapt more than 15% in after-hours trading following the report.</p>
<p>“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital, said. She made the comments this week during a video discussion about the trial results with other University of Chicago faculty members. The discussion was recorded and Stat obtained a copy of the video.</p>
<p>Virtual Event Virtual Clinical Trials Online This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance. Register Today!</p>
<p>The hospital recruited 125 patients into two phase 3 studies, including 113 with severe disease. The study has no control arm, with all of the patients receiving daily infusions of remdesivir.</p>
<p>RELATED: New Gilead remdesivir COVID-19 data show up old problems with limited data</p>
<p>Remdesivir, which was originally tested in Ebola patients, has emerged as one of the top near-term hopes for COVID-19 patients. In addition to carrying out its own clinical trials, Gilead has made the drug available to studies run by other sponsors, as well as to more than 1,700 people on a compassionate use basis. Last week, the New England Journal of Medicine published data from 53 patients with severe disease, but that data set also lacked a control group.</p>
<p>And that&rsquo;s a key point. In a note to clients, Jefferies analyst Michael Yee called the leaked results an “incremental positive,” but wrote that the short-term stock move &ldquo;will probably pull back in a bit given eventual broader awareness that this is not the actual phase 3 data.”</p>
<p>RELATED: Gilead shares slip as a 2nd remdesivir COVID-19 trial halted in China</p>
<p>“[We] reiterate that similar to the NEJM publication last week, today&rsquo;s reports are based on one site and there is no placebo. In fact, the Phase 3 severe study reading out in the next 1-2 weeks has no placebo and is just [5 days versus 10 days] of treatment,” he added.</p>
<p>Gilead expects to report data from a controlled study in patients with severe disease by the end of April, with data from a study of patients with moderate disease coming in late May.</p>
<p>“[If] the data looks similar to the NEJM results (10-20% mortality rate), then this is likely to be construed positive and could expand use,” Yee wrote.


<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
<ins class="adsbygoogle"
     style="display:block; text-align:center;"
     data-ad-layout="in-article"
     data-ad-format="fluid"
     data-ad-client="ca-pub-2730293094729387"
     data-ad-slot="6787193373"></ins>
<script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>

</p>

						
						
						
                    </div>
                    
                    
                    <div class="after-post-tags">


		
                    
                    </div>
                    
                    




                </div>
                
            </div>
        </div>
        
        
    </div>


            </div>
<div class="jumbotron fortags">
	<div class="d-md-flex h-100">
		<div class="col-md-4 transpdark align-self-center text-center h-100">
			<div class="d-md-flex align-items-center justify-content-center h-100">
				<h2 class="d-md-block d-none align-self-center py-1 font-weight-light">Explore <span class="d-none d-md-inline">→</span></h2>
			</div>
		</div>


	</div>
</div>

<footer class="footer">
    <div class="container">
        <div class="row">
            <div class="col-md-6 col-sm-6 text-center text-lg-left">
               m donation charity &copy; Copyright 
            </div>
        </div>
    </div>
</footer>


        </div>


<script src="https://code.jquery.com/jquery-3.4.1.min.js"></script>
    
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.6/umd/popper.min.js" integrity="sha384-wHAiFfRlMFy6i5SRaxvfOCifBUQy1xHdJ/yoi7FRNXMRBu5WHdZYu1hA6ZOblgut" crossorigin="anonymous"></script>

<script src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js" integrity="sha384-JjSmVgyd0p3pXB1rRibZUAYoIIy6OrQ6VrjIEaFf/nJGzIxFDsf4x0xIM+B07jRM" crossorigin="anonymous"></script>

<script src="http://www.4stack.pro/js/mediumish.js"></script>


<script>
var userLang = navigator.language || navigator.userLanguage;

	$("#mymenu").append(' <li class="nav-item"><a class="nav-link" href="http://www.4stack.pro/series/pop-rumor">News</a></li>'); 
	$("#navbar_top").html(' <a href="http://www.4stack.pro/series/pop-rumor">More Rumors➜➜</a>');

</script>


<script type="application/javascript">
var doNotTrack = false;
if (!doNotTrack) {
	(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	})(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
	ga('create', 'UA-153100602-3', 'auto');
	
	ga('send', 'pageview');
}
</script>

    </body>
</html>
